HKSE:2269

WuXi Biologics (Cayman) Inc. · HKSE · Healthcare · HKD · FY for 2025

Figures on this page computed 2026-11-08 13:44 UTC

Last close

n/aHKD

Market data

34.9xP/E
Price / Earnings per Share (diluted)
Source
computed
Taken on
2026-11-08
Reported in
HKD
- computed
- Computed from the filing for 2025
12.8%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Taken on
2026-11-08
Reported in
HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
22.5%Net margin
Net Income / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
12.8%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
0.07Debt/equity
Total Debt / Shareholders' Equity
Source
computed
Taken on
2026-11-08
Reported in
HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-08
Reported in
HKD
- computed

Price is the furthest below its sector's middle: 0.25 against 0.36 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Follow one yuan

lens 1 of 9

After what it costs to make

46.0%

After running the business

30.5%

After interest and tax

22.5%

After what it must reinvest

12.8%

Kept after the dividend

n/a

after what it costs to make, 46.0% of sales; after running the business, 30.5% of sales; after interest and tax, 22.5% of sales; after what it must reinvest, 12.8% of sales

The five stops

4 of 5 read

After what it costs to make10,018,512,00046.0%
After running the business6,639,745,00030.5%
After interest and tax4,908,343,00022.5%
After what it must reinvest2,798,736,00012.8%
Kept after the dividendn/an/a

The last stop is empty on purpose. This filing does not tag a common dividend, so what is kept after it cannot be worked out. That is not the same fact as a company that paid no dividend, and we will not print a zero for it.

What is left after the dividend is not held for this company.

Every figure in this lens

Except where said otherwise: Computed from the filing for 2025

Sales21,790,018,000
Source
computed
Statement
income
Fiscal year
2025
Reported in
CNY
After what it costs to make10,018,512,000
Source
computed
Statement
income
Fiscal year
2025
Reported in
CNY
After running the business6,639,745,000
Source
computed
Statement
income
Fiscal year
2025
Reported in
CNY
After interest and tax4,908,343,000
Source
computed
Statement
income
Fiscal year
2025
Reported in
CNY
After what it must reinvest2,798,736,000
Source
computed
Statement
income
Fiscal year
2025
Reported in
CNY
Kept after the dividendn/a
Not held.
Source
computed
Statement
income
Fiscal year
2025
Reported in
CNY